Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, t
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
12:11pm, Friday, 08'th May 2026
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 05'th May 2026
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
02:05pm, Thursday, 30'th Apr 2026
AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth.
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
04:42pm, Wednesday, 29'th Apr 2026
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Amarin Reports 2026 First Quarter Financial Results
07:00am, Wednesday, 29'th Apr 2026
Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Me
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
10:43am, Thursday, 23'rd Apr 2026
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
08:00am, Wednesday, 15'th Apr 2026
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that i
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks
01:15am, Saturday, 07'th Mar 2026
Amarin has one drug, and it has lost key patent protections. The company is cutting costs in an effort to generate positive cash flow.
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
09:25am, Thursday, 05'th Mar 2026
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
09:30am, Tuesday, 03'rd Mar 2026
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Amarin Q4 Earnings Call Highlights
02:38am, Saturday, 28'th Feb 2026
Amarin (NASDAQ: AMRN) executives told investors that 2025 marked a "substantial achievement" year as the company advanced a strategic pivot toward a more partnered international commercial model and e
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
10:25am, Thursday, 26'th Feb 2026
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
02:58pm, Wednesday, 25'th Feb 2026
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today iss
